Navigation Links
AlphaDetail AlphaPulse™: Anticipated Impact of CATT Trial in Wet AMD Treatment
Date:5/16/2011

SAN MATEO, Calif., May 16, 2011 /PRNewswire/ -- On April 28, 2011 the New England Journal of Medicine released highly anticipated one-year results of the ongoing "Comparisons of Age-Related Macular Degeneration Treatments Trials" (CATT).

AlphaDetail, Inc., a leader in global ophthalmology primary market research and influence network mapping, has conducted its latest AlphaPulse survey with 120 Ophthalmologists to gauge their reactions on the heels of this important news.

Amy Tsang, a Director at AlphaDetail, explained, "The use of Avastin vs. Lucentis in Wet AMD has been debated among eye care professionals for years, and many anticipated that these results could bring closure to the issue."

While results from the trial confirmed that Avastin is non-inferior to Lucentis on visual acuity efficacy measures, the results related to level of risk associated with serious adverse events are less definitive.

  • 68% of surveyed Ophthalmologists are currently aware of the CATT trial results.
  • Perceived Benefits of Avastin
    • Over three-quarters of Ophthalmologists agree that the results from the CATT trial provide evidence that Avastin's cost savings outweigh its potential risks in Wet AMD.
    • Avastin is currently the dominant anti-VEGF therapy used to treat Wet AMD in the United States and this dominance is expected to continue among newly diagnosed patients in the future.
    • Based on the CATT trial results, Ophthalmologists intend to switch10-15% of their Wet AMD patients currently on Lucentis to Avastin over the next 6 months.

  • Perceived Benefits of Lucentis
    • Two-thirds of Ophthalmologists agree that Lucentis' superiority over Avastin in other efficacy-related attributes, such as lowering retinal thickness and decreasing retinal fluid, are important considerations when selecting the appropriate therapy for their patients.
    • Similarly, two-thirds of Ophthalmologists agree that data supporting equivalent long term efficacy between Lucentis and Avastin is still needed.
    • Finally, Ophthalmologists are divided on their level of concern about mortality rates and risk of hemorrhagic stroke with Avastin compared to Lucentis as shown in an analysis of 77,886 Wet AMD patients on Medicare.

To learn more about this study and to receive full results, please contact Amy Tsang at Amy.Tsang@alphadetail.com or (650) 581-3127.

About AlphaDetail, Inc.:

At AlphaDetail, we have an unparalleled commitment to our clients. We are a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community. AlphaDetail is built on one of the industry's strongest foundations that includes a large team of exceptional analytical specialists, the industry's leading technology platform and a flexible approach to research that helps us to answer our clients' most challenging questions.


'/>"/>
SOURCE AlphaDetail, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panels Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.
2. AlphaDetail Tracking Study Enhancements: The Advantage of Integration and Speed
3. AlphaDetail, Inc. Enhances Methodology / Advanced Analytics Capabilities
4. AlphaDetail Revenue Soars 30% in 2010
5. AlphaDetail Commemorates 10-Year Anniversary by Community Volunteering
6. Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
7. Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotechs New Psoriasis Agent Stelara (ustekinumab) is High
8. New Mexico Software Enhances Technology Staff to Support Anticipated Sales Growth
9. TIGR® Matrix Surgical Mesh - Exhibited Ahead of Anticipated CE Mark Approval at European Hernia Society 2011, Ghent, Belgium
10. Hopkins Report: Focusing on Family Planning Lessens HIV Impact
11. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance ... a medical-grade battery-powered display stand specifically designed for endoscopy environments. An ... technology into a clinical solution to support the improvement of patient ... Innovative Design ... Wireless Solution ...
(Date:10/5/2017)... , Oct. 5, 2017  In response to ... Oral and Maxillofacial Surgeons (AAOMS) released prescribing recommendations ... to be used as a first-line therapy to ... Recognizing the value ... White Paper "Opioid Prescribing: Acute and Postoperative Pain ...
(Date:10/4/2017)... 2017 OBP Medical , a ... devices, today announced regulatory approval from ... Agência Nacional de Vigilância Sanitária (ANVISA)) to market ... retractor with integrated LED light source and smoke ... exposure of a tissue pocket or cavity during ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
(Date:10/12/2017)... ... 12, 2017 , ... Dr. Parsa Mohebi, the Los Angeles ... to the newly revamped Cosmetic Town journal section, featuring articles written ... known as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I ...
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand ... Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be ... Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the ... a year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, ... retirement havens have extremely low property-tax rates, which contributes to the relatively lower ...
Breaking Medicine News(10 mins):